Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: Results from the randomised phase III AVAGAST trial

British Journal of Cancer

Volumn 114, Issue 8, 2016, Pages 855-862

  Hacker, Ulrich T ^a   Escalona Espinosa, Laura ^b   Consalvo, Nicola ^c   Goede, Valentin ^d,e   Schiffmann, Lars ^d,e   Scherer, Stefan J ^f   Hedge, Priti ^g   Van Cutsem, Eric ^h   Coutelle, Oliver ^d,e   Büning, Hildegard ^b,i  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g GENENTECH INC   (United States)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

angiogenesis; Angiopoietin 2; bevacizumab; biomarker; gastric cancer; liver metastasis

Indexed keywords

ANGIOPOIETIN 2; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; FLUOROURACIL; PLACEBO; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; C11ORF2 PROTEIN, HUMAN; TUMOR MARKER; VESICULAR TRANSPORT PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; VERY ELDERLY; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; STOMACH NEOPLASMS;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; STOMACH NEOPLASMS; VESICULAR TRANSPORT PROTEINS;

EID: 84962071110     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.30     Document Type: Article

References (54)

1. Albini A, Noonan DM. (2012). Angiopoietin2 and Tie2: tied to lymphangiogenesis and lung metastasis. New perspectives in antimetastatic antiangiogenic therapy. J Natl Cancer Inst 104(6): 429-431
2. Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama K, Siewert JR. (1993). Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer 71(10): 2918-2925
3. Brenner H, Rothenbacher D, Arndt V. (2009). Epidemiology of stomach cancer. Methods Mol Biol 472: 467-477
4. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC. (2010). A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9(1): 145-156
5. Cancer Genome Atlas Research Network. (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517): 202-209
6. Chen Z, Zhu S, Hong J, Soutto M, Peng D, Belkhiri A, Xu Z, El-RifaiW(2015) Gastric tumour-derived ANGPT2 regulation by DARPP-32 promotes angiogenesis. Gut 0: 1-10
7. Cho YJ, Ma JE, Yun EY, Kim YE, Kim HC, Lee JD, Hwang YS, Jeong YY. (2011). Serum angiopoietin-2 levels are elevated during acute exacerbations of COPD. Respirology 16(2): 284-290
8. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, Thurston G. (2013). Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 73(1): 108-118
9. Ferrara N. (2010). Role of myeloid cells in vascular endothelial growth factorindependent tumor angiogenesis. Curr Opin Hematol 17(3): 219-224
10. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG. (2006). Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12(2): 235-239
11. Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. (2013). Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 73(6): 1649-1657
12. Gill S, Shah A, Le N, Cook EF, Yoshida EM. (2003). Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol 21(11): 2070-2076
13. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT. (2010). Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103(9): 1407-1414
14. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM. (2010). Complementary actions of inhibitors of Angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70(6): 2213-2223
15. Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ, Chen DS. (2013). Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19(4): 929-937
16. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, Augustin HG. (2009). Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 15(4): 1384-1392
17. Holopainen T, Saharinen P, D Amico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Helotera H, Tammela T, Benjamin LE, Yla-Herttuala S, Leow CC, Koh GY, Alitalo K. (2012). Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 104(6): 461-475
18. Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, Doppalapudi VR, Pirie-Shepherd S, Levin N, Bradshaw C, Woodnutt G, Lappe R, Bhat A. (2011). Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 17(5): 1001-1011
19. Im JH, Tapmeier T, Balathasan L, Gal A, Yameen S, Hill S, Smart S, Noterdaeme O, Kelly M, Brady M, Fu W, Kruse K, Bernhard EJ, Augustin HG, Muschel RJ. (2013). G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency. Int J Cancer 132(2): 315-326
20. Imanishi Y, Hu B, Jarzynka MJ, Guo P, Elishaev E, Bar-Joseph I, Cheng SY. (2007). Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res 67(9): 4254-4263
21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. (2011). Global cancer statistics. CA Cancer J Clin 61(2): 69-90
22. Jo MJ, Lee JH, Nam BH, Kook MC, Ryu KW, Choi IJ, Kim YW, Bae JM. (2009). Preoperative serum angiopoietin-2 levels correlate with lymph node status in patients with early gastric cancer. Ann Surg Oncol 16(7): 2052-2057
23. Kahlert C, Pecqueux M, Halama N, Dienemann H, Muley T, Pfannschmidt J, Lasitschka F, Klupp F, Schmidt T, Rahbari N, Reissfelder C, Kunz C, Benner A, Falk C, Weitz J, Koch M. (2014). Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases. Br J Cancer 110(2): 441-449
24. Kamangar F, Dores GM, Anderson WF. (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14): 2137-2150
25. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt Jr. CH, Brown 3rd JV, Covens A, Nagarkar RV, Davy M, Leath 3rd CA, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun YN, Vergote IB. (2012). Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4): 362-371
26. Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG, Munro K, Augustin HG, Thomas M. (2013). Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 19(24): 6730-6740
27. Kim H, Koh GY. (2011). Ang2, the instigator of inflammation. Blood 118(18): 4767-4768
28. Kim J, Sun CL, Mailey B, Prendergast C, Artinyan A, Bhatia S, Pigazzi A, Ellenhorn JD. (2010). Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 21(1): 152-160
29. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Okamura A, Takakura N, Suda T, Ushio Y. (2001). Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61(16): 6248-6254
30. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, Kim M, Kim KE, Kim H, Lim NK, Jeon CJ, Lee GM, Jeon BH, Nam DH, Sung HK, Nagy A, Yoo OJ, Koh GY. (2010). Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18(2): 171-184
31. Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, Aldape KD, Fuller GN, Gomez-Manzano C. (2006). Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 8(5): 419-428
32. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. (2015). Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 64: 1721-1731
33. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Group SIS. (2012). Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18(8): 2290-2300
34. Maffei R, Martinelli S, Santachiara R, Rossi D, Guarnotta C, Sozzi E, Zucchetto A, Rigolin GM, Fiorcari S, Castelli I, Fontana M, Coluccio V, Leonardi G, Zucchini P, Tripodo C, Cuneo A, Gattei V, Del Poeta G, Forconi F, Gaidano G, Torelli G, Marasca R. (2010). Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood 116(4): 584-592
35. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, De Palma M. (2011). Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19(4): 512-526
36. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. (2005). REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2(8): 416-422
37. Minami T, Jiang S, Schadler K, Suehiro J, Osawa T, Oike Y, Miura M, Naito M, Kodama T, Ryeom S. (2013). The calcineurin-NFATangiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep 4(4): 709-723
38. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae D-S, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, LhomméC, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. (2014). Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebocontrolled phase 3 trial. Lancet Oncol 15(8): 799-808
39. Murukesh N, Dive C, Jayson GC. (2010). Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 102(1): 8-18
40. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30): 3968-3976
41. Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, Oh YJ, Hwang SC. (2007). Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132(1): 200-206
42. Rigamonti N, De Palma M. (2013). A role for angiopoietin-2 in organ-specific metastasis. Cell Rep 4(4): 621-623
43. Rigamonti N, Kadioglu E, Keklikoglou I, Wyser Rmili C, Leow CC, De Palma M. (2014). Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep 8(3): 696-706
44. Scholz A, Lang V, Henschler R, Czabanka M, Vajkoczy P, Chavakis E, Drynski J, Harter PN, Mittelbronn M, Dumont DJ, Plate KH, Reiss Y. (2011). Angiopoietin-2 promotes myeloid cell infiltration in a beta(2)-integrin-dependent manner. Blood 118(18): 5050-5059
45. Schulz P, Fischer C, Detjen KM, Rieke S, Hilfenhaus G, von Marschall Z, Bohmig M, Koch I, Kehrberger J, Hauff P, Thierauch KH, Alves F, Wiedenmann B, Scholz A. (2011). Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. FASEB J 25(10): 3325-3335
46. Sfiligoi C, de Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, Biglia N, Audero E, Arisio R, Bussolino F, Sismondi P, De Bortoli M. (2003). Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 103(4): 466-474
47. Sheridan C. (2015). Amgen s angiopoietin blocker fails in ovarian cancer. Nat Biotechnol 33(1): 5-6
48. Silha JV, Krsek M, Sucharda P, Murphy LJ. (2005). Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 29: 1308-1314
49. Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel SS, Jugold M, Besemfelder E, Thomas M, Pasparakis M, Augustin HG. (2014). Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 26(6): 880-895
50. Tsoli M, Robertson G. (2013). Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab 24: 174-183
51. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA. (2012). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30(17): 2119-2127
52. Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ. (2011). Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 104(1): 51-59
53. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A. Group RS. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11): 1224-1235
54. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O Brien-Jenkins A, Randall TC, Rubin SC, Coukos G. (2003). Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63(12): 3403-3412